Adocia wins round one in Lilly legal battle

An arbitration panel has found in favor of French diabetes specialist Adocia (Euronext: ADOC) to resolve the first of its claims against US pharma major Eli Lilly (NYSE: LLY).

The companies’ attempts to collaborate on a diabetes program have twice broken down, leading to disputes over what Lilly owed Adocia and a host of other issues.

Adocia has been awarded $11.6 million as compensation by the American Arbitration Association panel for having earned a disputed contractual milestone payment. The Paris-based company will separately submit claims for interest, litigation fees and costs from the proceedings.